#151246

Anti-CDKN2A/p14ARF [ARF 4C6/4]

Cat. #151246

Anti-CDKN2A/p14ARF [ARF 4C6/4]

Cat. #: 151246

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 1-2 weeks

Target: p14 ARF

Class: Monoclonal

Application: ELISA ; IHC ; IF ; IP ; WB

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Institute: Cancer Research UK, London Research Institute: Lincoln's Inn Fields

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-CDKN2A/p14ARF [ARF 4C6/4]
  • Research fields: Cancer;Cell biology;Genetics
  • Clone: ARF 4C6/4
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Molecular weight: 14 kDa
  • Strain: Balb/c
  • Reactivity: Human
  • Host: Mouse
  • Application: ELISA ; IHC ; IF ; IP ; WB
  • Description: p14ARF is associated with the regulation of p53 and MDM2 and is deleted or methylated in many human cancers. The gene for CDK2NA generates several transcripts/proteins which differ from each other in their first exons. Three of these transcripts are generated by alternative splicing (isoform 1 a.k.a p16INK4A, isoform 2 and isoform 3 a.k.a p12), two of which are known to function as inhibitors of CDK4 kinase. One other transcript that is generated from this gene contains an alternate reading frame (ARF), with the first exon located 20kb upstream of the remainder of the gene(isoform 4 a.k.a. p14ARF, p19ARF, ARF). In spite of the structural and some functional differences, all the proteins encoded by the CDKN2A gene are involved in cell cycle G1 control.
  • Immunogen: His-tagged p14ARF protein expressed in bacteria.
  • Isotype: IgG2a
  • Myeloma used: Sp2/0-Ag14
  • Recommended controls: BT549 breast cancer cell line.

Target Details

  • Target: p14 ARF
  • Molecular weight: 14 kDa
  • Tissue cell line specificity: BT549 breast cancer cell line.
  • Target background: p14ARF is associated with the regulation of p53 and MDM2 and is deleted or methylated in many human cancers. The gene for CDK2NA generates several transcripts/proteins which differ from each other in their first exons. Three of these transcripts are generated by alternative splicing (isoform 1 a.k.a p16INK4A, isoform 2 and isoform 3 a.k.a p12), two of which are known to function as inhibitors of CDK4 kinase. One other transcript that is generated from this gene contains an alternate reading frame (ARF), with the first exon located 20kb upstream of the remainder of the gene(isoform 4 a.k.a. p14ARF, p19ARF, ARF). In spite of the structural and some Fn differences, all the proteins encoded by the CDKN2A gene are involved in cell cycle G1 control.

Applications

  • Application: ELISA ; IHC ; IF ; IP ; WB

Handling

  • Format: Liquid
  • Concentration: 1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: '-15° C to -25° C
  • Shipping conditions: Shipping at 4° C

References

  • Ma et al. 2007. Mol Biol Cell. 18(7):2630-5. PMID: 17494866.
  • Depletion of the nucleolar protein nucleostemin causes G1 cell cycle arrest via the p53 pathway.
  • p14ARF expression in invasive breast cancers and ductal carcinoma in situ--relationships to p53 and Hdm2.
  • Vestey et al. 2004. Breast Cancer Res. 6(5):R571-85. PMID: 15318938.
  • Clark et al. 2002. Oncogene. 21(29):4498-507. PMID: 12085228.
  • Multiple interacting domains contribute to p14ARF mediated inhibition of MDM2.
  • Llanos et al. 2001. Nat Cell Biol. 3(5):445-52. PMID: 11331871.
  • Stabilization of p53 by p14ARF without relocation of MDM2 to the nucleolus.